Clinical Trial

Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction

Study acronym: TELE-FASTER
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Research hypothesis: Fast telemonitored medical sequencing in patients with heart failure with reduced ejection fraction (HFrEF) is safe and feasible. Background: Modern therapy for HFrEF offers a highly effective arsenal of drugs, devices and interventional therapies, yet mortality and morbidity remain high in the cohort. One major problem is that drug therapy introduction and up titration has been very hard to implement in a majority of HFrEF patients. Most previous telemonitoring studies have focused on the continuous monitoring of patients and the monitoring itself has been the main intervention. A potentially more effective way to use telemonitoring in heart failure patients may be to combine the technique with a medical intervention when the patients are most vulnerable to heart failure events. The best therapeutic window lies in the period after newly diagnosed heart failure or right after a recent hospitalization following worsened chronic HFrEF. Method: We aim to use telemonitoring for fast sequencing of heart failure drugs for patients with HFrEF.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-11-25.
Status change: Recruiting → Active, Not Recruiting 2025-04-10
Trial Details
NCT Number NCT05637853
Lead Sponsor Göteborg University
Conditions Heart Failure With Reduced Ejection Fraction
Enrollment 60 participants
Start Date 2022-10-22
Primary Completion 2024-08-26 (estimated)
Study Completion 2026-08-26 (estimated)
Updated on ClinicalTrials.gov 2025-04-15